Abstract 5944
Background
Disruption of the immune system using immune checkpoint inhibitors (ICI) can result in a multitude of immune-related adverse effects (irAE). While irAEs have been well-reported in clinical trials, the impact and magnitude in the real world is unclear.
Methods
Data was collected on patients with advanced malignancy who experienced a suspected irAE requiring admission to an academic hospital (02/11-10/18). Each case was comprehensively reviewed by a minimum of two reviewers, including one sub-specialist.
Results
From 2011-2018, there were 632 hospitalizations for suspected irAEs, and the majority (59.7%; N = 377) were confirmed irAEs from immunotherapy: PD1 (N = 194, 51.5%), CTLA4 (N = 92, 24.4%), CTLA4 + PD1 (N = 76, 20.2%), PLD1 (N = 15, 4.0%). The most common irAEs were gastrointestinal (37.4%), pulmonary (14.9%), hepatic (13.5%), endocrine (16.2%), neurologic (9.0%), cardiac (6.9%), dermatologic (5.6%), rheumatologic (2.9%), hematologic (2.1%), renal (1.9%), and allergy (1.1%). 10.3% of admissions had multiple toxicities. Median length of stay was 5 days (IQR, 3-8). Majority of patients (89.1%) required continuation of immunosuppressive medication on discharge. Inpatient toxicity led to ICI discontinuation in 78.1% of admissions. Overall, there were 11.3 irAE admissions per 100 patients treated with ICI and 2.1 irAE admissions per 100 ICI administrations.
Conclusions
irAEs from ICI can result in prolonged hospitalizations, need for immunosuppression, and ICI discontinuation, which can have detrimental effects on oncologic outcomes. Consequently, there is a critical need for coordinated multidisciplinary approach, comprehensive provider education, and translational research programs for early detection and intervention.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5579 - Quality of informed consent in clinical trials patients
Presenter: Gianluca Catania
Session: Poster Display session 3
Resources:
Abstract
5147 - Patient's rights: Where do we stand?
Presenter: Maja Kozuh
Session: Poster Display session 3
Resources:
Abstract
1279 - The oncology nurse coordinator’s role in a digestive oncology department: Impact on patient and hospital
Presenter: Fouad Awada
Session: Poster Display session 3
Resources:
Abstract
1670 - Nursing model for a breast cancer unit at the Catalan Institute of Oncology
Presenter: Ana Rodriguez-ortega
Session: Poster Display session 3
Resources:
Abstract
3936 - Role of cancer nurse in the prevention and control of acute deterioration for oncohematologic patient
Presenter: Raquel Azor Portolés
Session: Poster Display session 3
Resources:
Abstract
2789 - Standardized nursing care in the department of radiotherapy of a network of cancer centres
Presenter: José Delgado
Session: Poster Display session 3
Resources:
Abstract
4482 - Exploring anxiety, depression and quality of life of ambulatory cancer patients during chemotherapy.
Presenter: Theodoula Adamakidou
Session: Poster Display session 3
Resources:
Abstract
3075 - Implementing a Cancer Survivorship Program for Individuals with Recurrent Breast Cancer
Presenter: Darcy Burbage
Session: Poster Display session 3
Resources:
Abstract
3869 - The perceptions of parents/guardians regarding their child/adolescent’s experience of reflexology or non-specific foot massage The perceptions of parents/guardians regarding their child/adolescents experience of reflexology or non-specific foot massage
Presenter: Patricia Fox
Session: Poster Display session 3
Resources:
Abstract
4064 - Quality of life in survivors of adult haematological malignancies
Presenter: Anita Immanuel
Session: Poster Display session 3
Resources:
Abstract